Watch All Shows Victor Davis Hanson Tony Kinnett Daily Signal Signal Sitdown

Watch All Shows Victor Davis Hanson Tony Kinnett Daily Signal Signal Sitdown

Home – Healthcare & Policy News – The Trump Administration’s Best Healthcare Idea Isn’t the One Getting Attention 

The Trump Administration’s Best Healthcare Idea Isn’t the One Getting Attention 

One reason pharmaceuticals cost so much: The Food and Drug Administration’s approval process takes up to 12 years to bring a new drug to market. The Trump administration has launched Operation Trialblazer to shorten that timeline. 

It’s one of Trump’s best healthcare proposals so far, one that reduces the government’s footprint in U.S. healthcare. It is a welcome departure from some of the Trump administration’s other prescription drug initiatives that, unfortunately, expand the role of government. 

The FDA approval process is divided into three phases. Phase 1 determines if a drug can be used safely in humans and, if so, at what dosage. Completing Phase 1 takes an average of 380 days and, in some cases, can stretch to 700 days. 

Other countries are taking advantage of the FDA’s slower pace. China has reduced its Phase 1 process to 60 days while Australia’s is about 70 days. The U.S. has lost its competitive edge as a result. In 2024, the number of drug trials registered in China was over 16,600 versus 9,100 in the U.S., according to the Journal of Clinical Epidemiology—the first time China has exceeded the U.S. 

China is seeing a surge of investment capital as a result. Out-licensing is the process by which a pharmaceutical company that develops a drug grants the rights to another company to further develop it. In 2023, pharmaceutical companies made $38 billion worth of out-licensing deals with Chinese firms. In 2024 that rose to nearly $52........

© The Daily Signal